Acorda Therapeutics Inc

NASDAQ ACORQ

Data sourced from iex and EODHD
Download Data

Acorda Therapeutics Inc Equity Multiplier for the Trailing 12 Months (TTM) ending March 31, 2024: -0.44

Acorda Therapeutics Inc Equity Multiplier is -0.44 for the Trailing 12 Months (TTM) ending March 31, 2024. The Equity Multiplier measures the proportion of a company's assets that are financed by equity. It indicates the level of financial leverage in a company's capital structure. A higher ratio suggests a higher level of debt financing and indicates higher financial risk. The equity multiplier is useful in assessing the company's solvency and financial stability.
NASDAQ: ACORQ

Acorda Therapeutics Inc

CEO -
IPO Date Feb. 10, 2006
Location United States
Headquarters 2 Blue Hill Plaza, Pearl River, NY, United States, 10965
Employees 102
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

StockViz Staff

September 19, 2024

Any question? Send us an email